Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/304% below fair value
$29.94−0.54 (-1.76%)
Close on Nov 13, 2026Market cap $1.54BP/E –Yield 0.00%
Immunocore ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was -$42.25M. The highest annual figure on record is -$42.25M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$42.25M | – |
| FY2024 | Dec 31, 2024 | -$66.26M | – |
| FY2023 | Dec 31, 2023 | -$55.55M | – |
| FY2022 | Dec 31, 2022 | -$46.41M | – |
| FY2021 | Dec 31, 2021 | -$166.99M | – |
See a number that looks wrong?